Orthofix International N.V. (Orthofix Medical Inc.) — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2011. The filing identifies the registrant as Orthofix International N.V. Amounts below are U.S. dollars; financial statement amounts are in millions unless noted.
Business context
Orthofix designs, manufactures, markets and distributes orthopedic medical products. From January 2011, it reported three global business units: Spine, Orthopedics and Sports Medicine, plus Corporate. Products include spinal and orthopedic implants, bone growth stimulators, biologics, bracing and sports-medicine products.
Financial performance
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Net sales | $144.7 | $138.9 | $427.5 | $420.6 |
| Gross profit | $108.7 | $106.6 | $323.4 | $321.5 |
| Gross margin | 75.1% | 76.8% | 75.7% | 76.4% |
| Operating income | $23.0 | $19.0 | $15.5 | $72.1 |
| Net income (loss) | $12.4 | $8.5 | ($13.5) | $36.2 |
| Diluted EPS | $0.66 | $0.48 | ($0.74) | $2.03 |
| Operating cash flow | Not presented by quarter | $39.6 | $29.8 |
- Q3 sales grew 4% reported, or 2% at constant currency. The nine-month increase was 2% reported and flat at constant currency.
- Q3 gross margin fell 1.7 percentage points year over year; management cited pricing pressure in U.S. spinal implants and Sports Medicine, product/geographic mix and currency effects.
- Nine-month operating income and earnings were materially affected by $46.0 million of charges related to U.S. Government inquiries. The prior-year period included a $12.3 million gain on the vascular-business sale.
- Q3 net income improved year over year, helped in part by lower net interest expense ($2.3 million versus $3.5 million). Nine-month net interest expense declined to $6.9 million from $14.8 million.
Segments and operating trends
- Spine: Q3 sales were $76.5 million, down 1%; nine-month sales were $225.6 million, down 1%. Stimulation sales fell 8% in Q3 and 9% year to date, attributed to lower industry procedures and sales-force changes; implants and biologics grew.
- Orthopedics: Q3 sales were $40.8 million, up 16% reported and 8% constant currency. Nine-month sales were $121.4 million, up 10% reported and 4% constant currency, led by hardware and biologics.
- Sports Medicine: Q3 sales were $25.6 million, up 8%; nine-month sales were $75.5 million, up 7%. Results included Omni Motion acquisition revenue of $1.2 million in Q3 and $3.0 million year to date. Q3 segment operating result was a $0.6 million loss, including product-liability litigation and settlement costs.
Liquidity, cash flow and debt
- September 30 cash and cash equivalents were $29.0 million, plus $37.2 million of restricted cash, for total cash balances of $66.2 million. Restricted cash was subject to credit-agreement restrictions.
- Current assets were $359.7 million and current liabilities $137.3 million. The current ratio was approximately 2.6, though restricted cash is not freely available to all group entities.
- Debt comprised $95.0 million under the term loan, $117.4 million under the revolving facility and $1.3 million of bank borrowings. The revolving facility had $82.6 million available; separate Italian lines had approximately $8.5 million available.
- Operating cash flow was $39.6 million for the first nine months, versus $29.8 million. It included a $46.0 million increase in accrued government-inquiry charges; working capital consumed approximately $24 million. Investing activities used $22.6 million, including $17.3 million of capital expenditures and the Omni Motion acquisition. Financing activities used $1.5 million.
- The credit facilities carry floating rates; the effective rate was 3.4%. Management reported covenant compliance at quarter end and expected continued compliance. A one-percentage-point rate increase was estimated to raise annual interest expense by approximately $2.1 million.
Material changes, outlook and risks
- In 2011, Orthofix recorded $43.0 million for a probable settlement of government matters concerning bone growth stimulator promotion and marketing, and a separate $3.0 million accrual for potential FCPA fines and penalties related to its former Mexican orthopedic distribution entity. Final terms were not settled as of the filing; additional loss on the FCPA matter was not reasonably estimable.
- The company stated it believed the recorded government-inquiry costs were probable of being incurred and paid in 2011. It planned to use available cash and draw on its revolver as needed. It said cash, projected operating cash flow and available credit were sufficient for near-term settlement, working-capital and capital-expenditure needs.
- Management’s stated priorities for 2011 included successful product launches, improving distribution coverage and quality, lowering operating expenses relative to revenue, and navigating or resolving government investigations. The filing provides no numerical revenue or earnings guidance.
- Other notable contingencies include unresolved Blackstone-related government investigations and claims, Sports Medicine product-liability litigation, and a DOJ investigation concerning former local-infusion-pump products. The filing states that some possible losses cannot currently be estimated. A $15.5 million escrow receivable related to Blackstone matters depends on contested indemnification claims and collection.
- Management cited pricing pressure, lower procedure volumes, reimbursement and regulatory changes, competition, product acceptance, litigation and investigation outcomes, foreign-exchange movements, and floating-rate debt as risks. It reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Final settlement terms, payment timing and total costs for the bone-growth-stimulation investigation, and whether the $43.0 million accrual is adequate.
- Progress and potential exposure from the Promeca FCPA matter, including whether losses could exceed the $3.0 million accrual.
- Recoverability of the $15.5 million Blackstone escrow receivable and the remaining indemnification funds.
- Whether Spine stimulation sales stabilize and whether Orthopedics and Sports Medicine growth persists excluding currency and acquisition contributions.
- Accessible liquidity after restricted cash, settlement payments and working-capital needs, alongside covenant headroom and floating-rate exposure.
- Ongoing product-liability claims, insurance coverage disputes and any developments in the DOJ infusion-pump investigation.